{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:06:26Z","timestamp":1780524386775,"version":"3.54.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00415-024-12871-7","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T13:19:28Z","timestamp":1736947168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Plasma alpha-synuclein predicts cognitive impairment in Parkinson\u2019s disease: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"272","author":[{"given":"Ziyue","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Cordato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renfen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boaz","family":"Shulruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0481-3933","authenticated-orcid":false,"given":"Daniel Kam Yin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"12871_CR1","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B (2007) Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord 22:1689\u20131707","journal-title":"Mov Disord"},{"key":"12871_CR2","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1750-3639.2009.00369.x","volume":"20","author":"D Aarsland","year":"2010","unstructured":"Aarsland D, Kurz MW (2010) The epidemiology of dementia associated with Parkinson\u2019s disease. Brain Pathol 20:633\u2013639","journal-title":"Brain Pathol"},{"key":"12871_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","volume":"27","author":"I Litvan","year":"2012","unstructured":"Litvan I, Goldman JG, Tr\u00f6ster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M (2012) Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: movement disorder society task force guidelines. Mov Disord 27:349\u2013356","journal-title":"Mov Disord"},{"key":"12871_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/mds.27902","volume":"35","author":"C Baiano","year":"2020","unstructured":"Baiano C, Barone P, Trojano L, Santangelo G (2020) Prevalence and clinical aspects of mild cognitive impairment in Parkinson\u2019s disease: a meta-analysis. Mov Disord 35:45\u201354","journal-title":"Mov Disord"},{"key":"12871_CR5","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1212\/WNL.56.6.730","volume":"56","author":"D Aarsland","year":"2001","unstructured":"Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-S\u00f8rensen P (2001) Risk of dementia in Parkinson\u2019s disease: a community-based, prospective study. Neurology 56:730\u2013736","journal-title":"Neurology"},{"key":"12871_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1590\/S1980-57642009DN20400005","volume":"2","author":"JL Otero","year":"2008","unstructured":"Otero JL (2008) Dementia with Parkinson disease: clinical diagnosis, neuropsychological aspects and treatment. Dement Neuropsychol 2:261\u2013266","journal-title":"Dement Neuropsychol"},{"key":"12871_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2377-13-35","volume":"13","author":"DJM McGhee","year":"2013","unstructured":"McGhee DJM, Royle PL, Thompson PA, Wright DE, Zajicek JP, Counsell CE (2013) A systematic review of biomarkers for disease progression in Parkinson\u2019s disease. BMC Neurol 13:35","journal-title":"BMC Neurol"},{"key":"12871_CR8","doi-asserted-by":"crossref","unstructured":"Kivis\u00e4kk P, Magdamo C, Trombetta BA, Noori A, Kuo YkE, Chibnik LB, Carlyle BC, Serrano-Pozo A, Scherzer CR, Hyman BT, Das S, Arnold SE (2022) Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment. Brain Commun 4:fcac155","DOI":"10.1093\/braincomms\/fcac155"},{"key":"12871_CR9","doi-asserted-by":"crossref","unstructured":"Paolini Paoletti F, Gaetani L, Parnetti L (2020) The challenge of disease-modifying therapies in Parkinson\u2019s disease: role of CSF biomarkers. Biomolecules 10:335","DOI":"10.3390\/biom10020335"},{"key":"12871_CR10","doi-asserted-by":"crossref","unstructured":"Magalh\u00e3es P, Lashuel HA (2022) Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson\u2019s disease and other synucleinopathies. npj Parkinson\u2019s Dis 8:93","DOI":"10.1038\/s41531-022-00357-0"},{"key":"12871_CR11","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s12035-023-03212-2","volume":"60","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhang C, He X-Z, Li Z-H, Meng J-C, Mao R-T, Li X, Xue R, Gui Q, Zhang G-X, Wang L-H (2023) Interaction between the glymphatic system and \u03b1-synuclein in Parkinson\u2019s disease. Mol Neurobiol 60:2209\u20132222","journal-title":"Mol Neurobiol"},{"key":"12871_CR12","doi-asserted-by":"crossref","unstructured":"Al-Bachari S, Naish JH, Parker GJM, Emsley HCA, Parkes LM (2020) Blood\u2013brain barrier leakage is increased in Parkinson\u2019s disease. Front Physiol 11","DOI":"10.3389\/fphys.2020.593026"},{"key":"12871_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.peptides.2014.09.018","volume":"62","author":"Y-T Sui","year":"2014","unstructured":"Sui Y-T, Bullock KM, Erickson MA, Zhang J, Banks WA (2014) Alpha synuclein is transported into and out of the brain by the blood\u2013brain barrier. Peptides 62:197\u2013202","journal-title":"Peptides"},{"key":"12871_CR14","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/jnnp-2016-314857","volume":"88","author":"C-H Lin","year":"2017","unstructured":"Lin C-H, Yang S-Y, Horng H-E, Yang C-C, Chieh J-J, Chen H-H, Liu B-H, Chiu M-J (2017) Plasma \u03b1-synuclein predicts cognitive decline in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 88:818\u2013824","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12871_CR15","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/acn3.729","volume":"6","author":"ASL Ng","year":"2019","unstructured":"Ng ASL, Tan YJ, Lu Z, Ng EYL, Ng SYE, Chia NSY, Setiawan F, Xu Z, Tay KY, Prakash KM, Au WL, Tan E-K, Tan LCS (2019) Plasma alpha-synuclein detected by single molecule array is increased in PD. Ann Clin Transl Neurol 6:615\u2013619","journal-title":"Ann Clin Transl Neurol"},{"key":"12871_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000112832","volume":"5","author":"R Barbour","year":"2008","unstructured":"Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, Fox M, Goldstein JM, Soriano F, Seubert P, Chilcote TJ (2008) Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 5:55\u201359","journal-title":"Neurodegener Dis"},{"key":"12871_CR17","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3233\/JPD-212694","volume":"11","author":"P Youssef","year":"2021","unstructured":"Youssef P, Kim WS, Halliday GM, Lewis SJG, Dzamko N (2021) Comparison of different platform immunoassays for the measurement of plasma alpha-synuclein in Parkinson\u2019s disease patients. J Parkinsons Dis 11:1761\u20131772","journal-title":"J Parkinsons Dis"},{"key":"12871_CR18","doi-asserted-by":"publisher","first-page":"124903","DOI":"10.1016\/j.talanta.2023.124903","volume":"265","author":"Y Wu","year":"2023","unstructured":"Wu Y, Fu Y, Guo J, Guo J (2023) Single-molecule immunoassay technology: recent advances. Talanta 265:124903","journal-title":"Talanta"},{"key":"12871_CR19","doi-asserted-by":"publisher","first-page":"105358","DOI":"10.1016\/j.neuint.2022.105358","volume":"158","author":"H-H Tsao","year":"2022","unstructured":"Tsao H-H, Huang C-G, Wu Y-R (2022) Detection and assessment of alpha-synuclein in Parkinson disease. Neurochem Int 158:105358","journal-title":"Neurochem Int"},{"key":"12871_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00702-019-02137-2","volume":"127","author":"A Bougea","year":"2020","unstructured":"Bougea A, Stefanis L, Emmanouilidou E, Vekrelis K, Kapaki E (2020) High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases. J Neural Transm 127:311\u2013322","journal-title":"J Neural Transm"},{"key":"12871_CR21","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"12871_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13643-016-0215-7","volume":"5","author":"WM Bramer","year":"2016","unstructured":"Bramer WM, Giustini D, Kramer BMR (2016) Comparing the coverage, recall, and precision of searches for 120 systematic reviews in Embase, MEDLINE, and Google Scholar: a prospective study. Syst Rev 5:39","journal-title":"Syst Rev"},{"key":"12871_CR23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.5195\/jmla.2018.283","volume":"106","author":"WM Bramer","year":"2018","unstructured":"Bramer WM, de Jonge GB, Rethlefsen ML, Mast F, Kleijnen J (2018) A systematic approach to searching: an efficient and complete method to develop literature searches. J Med Libr Assoc 106:531\u2013541","journal-title":"J Med Libr Assoc"},{"key":"12871_CR24","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30:1591\u20131601","journal-title":"Mov Disord"},{"key":"12871_CR25","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/mds.27362","volume":"33","author":"RB Postuma","year":"2018","unstructured":"Postuma RB, Poewe W, Litvan I, Lewis S, Lang AE, Halliday G, Goetz CG, Chan P, Slow E, Seppi K, Schaffer E, Rios-Romenets S, Mi T, Maetzler C, Li Y, Heim B, Bledsoe IO, Berg D (2018) Validation of the MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 33:1601\u20131608","journal-title":"Mov Disord"},{"key":"12871_CR26","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MMG, Sterne JAC, Bossuyt PMM (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529\u2013536","journal-title":"Ann Intern Med"},{"key":"12871_CR27","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","volume":"368","author":"M Campbell","year":"2020","unstructured":"Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, Hartmann-Boyce J, Ryan R, Shepperd S, Thomas J, Welch V, Thomson H (2020) Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ 368:l6890","journal-title":"BMJ"},{"key":"12871_CR28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/jrsm.1060","volume":"4","author":"HJ Thomson","year":"2013","unstructured":"Thomson HJ, Thomas S (2013) The effect direction plot: visual display of non-standardised effects across multiple outcome domains. Res Synth Methods 4:95\u2013101","journal-title":"Res Synth Methods"},{"key":"12871_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/jrsm.1458","volume":"12","author":"MH Boon","year":"2021","unstructured":"Boon MH, Thomson H (2021) The effect direction plot revisited: application of the 2019 Cochrane Handbook guidance on alternative synthesis methods. Res Synth Methods 12:29\u201333","journal-title":"Res Synth Methods"},{"key":"12871_CR30","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (2019) Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration, Hoboken, New Jersey","DOI":"10.1002\/9781119536604"},{"key":"12871_CR31","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/psych4040049","volume":"4","author":"S Sen","year":"2022","unstructured":"Sen S, Yildirim I (2022) A tutorial on how to conduct meta-analysis with IBM SPSS statistics. Psych 4:640\u2013667","journal-title":"Psych"},{"key":"12871_CR32","doi-asserted-by":"publisher","first-page":"d549","DOI":"10.1136\/bmj.d549","volume":"342","author":"RD Riley","year":"2011","unstructured":"Riley RD, Higgins JPT, Deeks JJ (2011) Interpretation of random effects meta-analyses. BMJ 342:d549","journal-title":"BMJ"},{"key":"12871_CR33","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JAC Sterne","year":"2011","unstructured":"Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, Carpenter J, R\u00fccker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JPT (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343:d4002","journal-title":"BMJ"},{"key":"12871_CR34","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/jrsm.1260","volume":"8","author":"R Suurmond","year":"2017","unstructured":"Suurmond R, van Rhee H, Hak T (2017) Introduction, comparison, and validation of meta-essentials: a free and simple tool for meta-analysis. Res Synth Methods 8:537\u2013553","journal-title":"Res Synth Methods"},{"key":"12871_CR35","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1037\/0033-2909.86.3.638","volume":"86","author":"R Rosenthal","year":"1979","unstructured":"Rosenthal R (1979) The \u2018file drawer\u2019 problem and tolerance for null results. Psychol Bull 86:638\u2013641","journal-title":"Psychol Bull"},{"key":"12871_CR36","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13643-019-1131-4","volume":"8","author":"T Mathes","year":"2019","unstructured":"Mathes T, Pieper D (2019) An algorithm for the classification of study designs to assess diagnostic, prognostic and predictive test accuracy in systematic reviews. Syst Rev 8:226","journal-title":"Syst Rev"},{"key":"12871_CR37","doi-asserted-by":"crossref","unstructured":"van Rhee H, Suurmond R, Hak T (2015) User manual for meta-essentials: workbooks for meta-analysis. Erasmus Research Institute of Management","DOI":"10.2139\/ssrn.3241355"},{"key":"12871_CR38","doi-asserted-by":"crossref","unstructured":"Song Z, Shen J, Liu Y, Du X, Wu Y, Liu X, Zhang J (2021) Lower plasma \u03b1-synuclein levels are associated with cognitive impairment in Parkinson\u2019s disease. Clin Lab 67","DOI":"10.7754\/Clin.Lab.2020.200852"},{"key":"12871_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.parkreldis.2022.06.001","volume":"99","author":"M Zubelzu","year":"2022","unstructured":"Zubelzu M, Morera-Herreras T, Irastorza G, G\u00f3mez-Esteban JC, Murueta-Goyena A (2022) Plasma and serum alpha-synuclein as a biomarker in Parkinson\u2019s disease: a meta-analysis. Parkinsonism Relat Disord 99:107\u2013115","journal-title":"Parkinsonism Relat Disord"},{"key":"12871_CR40","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, Calabresi P (2019) CSF and blood biomarkers for Parkinson\u2019s disease. Lancet Neurol 18:573\u2013586","journal-title":"Lancet Neurol"},{"key":"12871_CR41","doi-asserted-by":"crossref","unstructured":"Lin C-H, Chiu S-I, Chen T-F, Jang J-SR, Chiu M-J (2020) Classifications of neurodegenerative disorders using a multiplex blood biomarkers-based machine learning model. Int J Mol Sci 21","DOI":"10.3390\/ijms21186914"},{"key":"12871_CR42","doi-asserted-by":"crossref","unstructured":"Samat NA, Abdul Murad NA, Mohamad K, Abdul Razak MR, Mohamed Ibrahim N (2017) Apolipoprotein E\u03b54: a biomarker for executive dysfunction among Parkinson\u2019s disease patients with mild cognitive impairment. Front Neurosci 11","DOI":"10.3389\/fnins.2017.00712"},{"key":"12871_CR43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12951-016-0198-5","volume":"14","author":"S-Y Yang","year":"2016","unstructured":"Yang S-Y, Chiu M-J, Lin C-H, Horng H-E, Yang C-C, Chieh J-J, Chen H-H, Liu B-H (2016) Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles. J Nanobiotechnol 14:41","journal-title":"J Nanobiotechnol"},{"key":"12871_CR44","doi-asserted-by":"publisher","first-page":"6530","DOI":"10.1007\/s00415-022-11301-w","volume":"269","author":"C-H Li","year":"2022","unstructured":"Li C-H, Chen T-F, Peng P-L, Lin C-H (2022) A task-specific cognitive domain decline is correlated with plasma and neuroimaging markers in patients with Parkinson\u2019s disease. J Neurol 269:6530\u20136543","journal-title":"J Neurol"},{"key":"12871_CR45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3233\/JPD-191766","volume":"10","author":"CH Chen","year":"2020","unstructured":"Chen CH, Lee BC, Lin CH (2020) Integrated plasma and neuroimaging biomarkers associated with motor and cognition severity in Parkinson\u2019s disease. J Parkinsons Dis 10:77\u201388","journal-title":"J Parkinsons Dis"},{"key":"12871_CR46","doi-asserted-by":"publisher","unstructured":"Huang CC, Chen PH, Tsai CC, Chiang HF, Hsieh CC, Chen TL, Liao WH, Chen YL, Wang JJ (2023) Diffusion and structural MRI as potential biomarkers in people with Parkinson\u2019s disease and cognitive impairment. Preprint at https:\/\/doi.org\/10.1007\/s00330-023-10012-8","DOI":"10.1007\/s00330-023-10012-8"},{"key":"12871_CR47","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/ane.13517","volume":"145","author":"W-T Lin","year":"2022","unstructured":"Lin W-T, Shaw J-S, Cheng F-Y, Chen P-H (2022) Plasma total tau predicts executive dysfunction in Parkinson\u2019s disease. Acta Neurol Scand 145:30\u201337","journal-title":"Acta Neurol Scand"},{"key":"12871_CR48","first-page":"105","volume":"26","author":"C Feng","year":"2014","unstructured":"Feng C, Wang H, Lu N, Chen T, He H, Lu Y, Tu XM (2014) Log-transformation and its implications for data analysis. Shanghai Arch Psychiatry 26:105\u2013109","journal-title":"Shanghai Arch Psychiatry"},{"key":"12871_CR49","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s13273-020-00104-7","volume":"16","author":"KH Shim","year":"2020","unstructured":"Shim KH, Kim SC, Youn YC, Sung Y-H, An SSA (2020) Decreased plasma \u03b1-synuclein in idiopathic Parkinson\u2019s disease patients after adjusting hemolysis factor. Mol Cell Toxicol 16:477\u2013484","journal-title":"Mol Cell Toxicol"},{"key":"12871_CR50","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/mds.27090","volume":"32","author":"B Mollenhauer","year":"2017","unstructured":"Mollenhauer B, Batrla R, El-Agnaf O, Galasko DR, Lashuel HA, Merchant KM, Shaw LM, Selkoe DJ, Umek R, Vanderstichele H, Zetterberg H, Zhang J, Caspell-Garcia C, Coffey C, Hutten SJ, Frasier M, Taylor P (2017) A user\u2019s guide for \u03b1-synuclein biomarker studies in biological fluids: perianalytical considerations. Mov Disord 32:1117\u20131130","journal-title":"Mov Disord"},{"key":"12871_CR51","doi-asserted-by":"crossref","unstructured":"Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, van Duijn E, Goetz CG, Weintraub D, Stebbins GT, Martinez-Martin P, the members of the MDSRSRC (2018) Global scales for cognitive screening in Parkinson\u2019s disease: critique and recommendations. Mov Disord 33:208\u2013218","DOI":"10.1002\/mds.27233"},{"key":"12871_CR52","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1093\/aje\/kwr243","volume":"174","author":"C Proust-Lima","year":"2011","unstructured":"Proust-Lima C, Dartigues JF, Jacqmin-Gadda H (2011) Misuse of the linear mixed model when evaluating risk factors of cognitive decline. Am J Epidemiol 174:1077\u20131088","journal-title":"Am J Epidemiol"},{"key":"12871_CR53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000365637","volume":"43","author":"V Philipps","year":"2014","unstructured":"Philipps V, Amieva H, Andrieu S, Dufouil C, Berr C, Dartigues J-F, Jacqmin-Gadda H, Proust-Lima C (2014) Normalized mini-mental state examination for assessing cognitive change in population-based brain aging studies. Neuroepidemiology 43:15\u201325","journal-title":"Neuroepidemiology"},{"key":"12871_CR54","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12877-015-0103-3","volume":"15","author":"PT Trzepacz","year":"2015","unstructured":"Trzepacz PT, Hochstetler H, Wang S, Walker B, Saykin AJ (2015) Relationship between the montreal cognitive assessment and mini-mental state examination for assessment of mild cognitive impairment in older adults. BMC Geriatr 15:107","journal-title":"BMC Geriatr"},{"key":"12871_CR55","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1590\/s1980-5764-2016dn1004013","volume":"10","author":"V Tumas","year":"2016","unstructured":"Tumas V, Borges V, Ballalai-Ferraz H, Zabetian CP, Mata IF, Brito MMC, Foss MP, Novaretti N, Santos-Lobato BL (2016) Some aspects of the validity of the Montreal Cognitive Assessment (MoCA) for evaluating cognitive impairment in Brazilian patients with Parkinson\u2019s disease. Dement Neuropsychol 10:333\u2013338","journal-title":"Dement Neuropsychol"},{"key":"12871_CR56","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/archneur.56.7.857","volume":"56","author":"CM Clark","year":"1999","unstructured":"Clark CM, Sheppard L, Fillenbaum GG, Galasko D, Morris JC, Koss E, Mohs R, Heyman A (1999) Variability in annual mini-mental state examination score in patients with probable Alzheimer disease: a clinical perspective of data from the consortium to establish a registry for Alzheimer\u2019s disease. Arch Neurol 56:857\u2013862","journal-title":"Arch Neurol"},{"key":"12871_CR57","doi-asserted-by":"crossref","unstructured":"Lin C-H, Yang S-Y, Horng H-E, Yang C-C, Chieh J-J, Chen H-H, Liu B-H, Chiu M-J (2018) Plasma biomarkers differentiate Parkinson\u2019s disease from atypical parkinsonism syndromes. Front Aging Neurosci 10","DOI":"10.3389\/fnagi.2018.00123"},{"key":"12871_CR58","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1057\/jt.2009.5","volume":"17","author":"B Ratner","year":"2009","unstructured":"Ratner B (2009) The correlation coefficient: its values range between +1\/\u22121, or do they? J Target Meas Anal Mark 17:139\u2013142","journal-title":"J Target Meas Anal Mark"},{"key":"12871_CR59","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00702-013-0972-6","volume":"120","author":"G Caranci","year":"2013","unstructured":"Caranci G, Piscopo P, Rivabene R, Traficante A, Riozzi B, Castellano AE, Ruggieri S, Vanacore N, Confaloni A (2013) Gender differences in Parkinson\u2019s disease: focus on plasma alpha-synuclein. J Neural Transm 120:1209\u20131215","journal-title":"J Neural Transm"},{"key":"12871_CR60","doi-asserted-by":"publisher","first-page":"e0123444","DOI":"10.1371\/journal.pone.0123444","volume":"10","author":"NKU Koehler","year":"2015","unstructured":"Koehler NKU, Stransky E, Meyer M, Gaertner S, Shing M, Schnaidt M, Celej MS, Jovin TM, Leyhe T, Laske C, Batra A, Buchkremer G, Fallgatter AJ, Wernet D, Richartz-Salzburger E (2015) Alpha-synuclein levels in blood plasma decline with healthy aging. PLoS ONE 10:e0123444","journal-title":"PLoS ONE"},{"key":"12871_CR61","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/srep02540","volume":"3","author":"PG Foulds","year":"2013","unstructured":"Foulds PG, Diggle P, Mitchell JD, Parker A, Hasegawa M, Masuda-Suzukake M, Mann DMA, Allsop D (2013) A longitudinal study on \u03b1-synuclein in blood plasma as a biomarker for Parkinson\u2019s disease. Sci Rep 3:2540","journal-title":"Sci Rep"},{"key":"12871_CR62","doi-asserted-by":"crossref","unstructured":"Chen N-C, Chen H-L, Li S-H, Chang Y-H, Chen M-H, Tsai N-W, Yu C-C, Yang S-Y, Lu C-H, Lin W-C (2020) Plasma levels of \u03b1-synuclein, A\u03b2-40 and T-tau as biomarkers to predict cognitive impairment in Parkinson\u2019s disease. Front Aging Neurosci 12","DOI":"10.3389\/fnagi.2020.00112"},{"key":"12871_CR63","doi-asserted-by":"publisher","first-page":"6377","DOI":"10.1007\/s00415-022-11287-5","volume":"269","author":"DKY Chan","year":"2022","unstructured":"Chan DKY, Chen J, Chen RF, Parikh J, Xu YH, Silburn PA, Mellick GD (2022) Plasma biomarkers inclusive of \u03b1-synuclein\/amyloid-beta40 ratio strongly correlate with Mini-Mental State Examination score in Parkinson\u2019s disease and predict cognitive impairment. J Neurol 269:6377\u20136385","journal-title":"J Neurol"},{"key":"12871_CR64","doi-asserted-by":"crossref","unstructured":"Ganguly U, Singh S, Pal S, Prasad S, Agrawal BK, Saini RV, Chakrabarti S (2021) Alpha-synuclein as a biomarker of parkinson\u2019s disease: good, but not good enough. Front Aging Neurosci 13","DOI":"10.3389\/fnagi.2021.702639"},{"key":"12871_CR65","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s13311-023-01379-z","volume":"20","author":"DG Coughlin","year":"2023","unstructured":"Coughlin DG, Irwin DJ (2023) Fluid and biopsy based biomarkers in Parkinson\u2019s disease. Neurotherapeutics 20:932\u2013954","journal-title":"Neurotherapeutics"},{"key":"12871_CR66","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00702-019-02001-3","volume":"126","author":"R Yilmaz","year":"2019","unstructured":"Yilmaz R, Hopfner F, van Eimeren T, Berg D (2019) Biomarkers of Parkinson\u2019s disease: 20 years later. J Neural Transm 126:803\u2013813","journal-title":"J Neural Transm"},{"key":"12871_CR67","doi-asserted-by":"crossref","unstructured":"Chen PC, Yu CC, Chen YS, Lu CH, Chan SH, Chou KH, Chen MH, Lin WC (2021) The potential effects of oxidative stress-related plasma abnormal protein aggregate levels on brain volume and its neuropsychiatric consequences in Parkinson\u2019s disease. Oxid Med Cell Longev","DOI":"10.1155\/2021\/3666327"},{"key":"12871_CR68","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1007\/s10072-022-06093-w","volume":"43","author":"M Li","year":"2022","unstructured":"Li M, Shi X, Ma J, Sun W, Wang Z, Li D, Zheng J, Zhao Z, Gu Q, Chen S (2022) Plasma arylsulfatase A levels are associated with cognitive function in Parkinson\u2019s disease. Neurol Sci 43:4753\u20134759","journal-title":"Neurol Sci"},{"key":"12871_CR69","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000510325","volume":"49","author":"W-C Lin","year":"2020","unstructured":"Lin W-C, Lu C-H, Chiu P-Y, Yang S-Y (2020) Plasma total \u03b1-synuclein and neurofilament light chain: clinical validation for discriminating Parkinson\u2019s disease from normal control. Dement Geriatr Cogn Disord 49:401\u2013409","journal-title":"Dement Geriatr Cogn Disord"},{"key":"12871_CR70","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3174\/ajnr.A7171","volume":"42","author":"WC Lin","year":"2021","unstructured":"Lin WC, Lee PL, Lu CH, Lin CP, Chou KH (2021) Linking stage-specific plasma biomarkers to gray matter atrophy in Parkinson disease. AJNR Am J Neuroradiol 42:1444","journal-title":"AJNR Am J Neuroradiol"},{"key":"12871_CR71","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pjnns.2017.11.009","volume":"52","author":"M Malec-Litwinowicz","year":"2018","unstructured":"Malec-Litwinowicz M, Plewka A, Plewka D, Bogunia E, Morek M, Szczudlik A, Szubiga M, Rudzi\u0144ska-Bar M (2018) The relation between plasma \u03b1-synuclein level and clinical symptoms or signs of Parkinson\u2019s disease. Neurol Neurochir Pol 52:243","journal-title":"Neurol Neurochir Pol"},{"key":"12871_CR72","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/jnc.15601","volume":"161","author":"J Ren","year":"2022","unstructured":"Ren J, Pan C, Wang Y, Xue C, Lin H, Xu J, Wang H, Zhang W, Xu P, Chen Y, Liu W (2022) Plasma \u03b1-synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson\u2019s disease. J Neurochem 161:506\u2013515","journal-title":"J Neurochem"},{"key":"12871_CR73","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3889\/oamjms.2022.7940","volume":"10","author":"Y Syafrita","year":"2022","unstructured":"Syafrita Y, Istarini A, Busra M, Indra S, Susanti R (2022) Relationship between plasma level of beta-amyloid, alpha-synuclein, and tau protein with cognitive impairment in Parkinson disease. Open Access Maced J Med Sci 10:663\u2013667","journal-title":"Open Access Maced J Med Sci"},{"key":"12871_CR74","doi-asserted-by":"publisher","first-page":"7115","DOI":"10.1038\/s41598-021-86617-0","volume":"11","author":"H-H Tsai","year":"2021","unstructured":"Tsai H-H, Tsai L-K, Lo Y-L, Lin C-H (2021) Amyloid related cerebral microbleed and plasma A\u03b240 are associated with cognitive decline in Parkinson\u2019s disease. Sci Rep 11:7115","journal-title":"Sci Rep"},{"key":"12871_CR75","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1021\/acschemneuro.2c00565","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Ning H, Ren J, Pan C, Yu M, Xue C, Wang X, Zhou G, Chen Y, Liu W (2022) Integrated clinical features with plasma and multi-modal neuroimaging biomarkers to diagnose mild cognitive impairment in early drug-naive Parkinson\u2019s disease. ACS Chem Neurosci 13:3523\u20133533","journal-title":"ACS Chem Neurosci"},{"key":"12871_CR76","doi-asserted-by":"crossref","unstructured":"Zhao X, He H, Xiong X, Ye Q, Feng F, Zhou S, Chen W, Xia K, Qian S, Yang Y, Xie C (2022) Lewy body-associated proteins A-synuclein (a-syn) as a plasma-based biomarker for Parkinson\u2019s disease. Front Aging Neurosci 14","DOI":"10.3389\/fnagi.2022.869797"}],"updated-by":[{"DOI":"10.1007\/s00415-025-13021-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000}}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12871-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12871-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12871-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T07:02:23Z","timestamp":1745305343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12871-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["12871"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12871-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00415-025-13021-3","asserted-by":"object"}]},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In table 4, colours in the entries \u201cLow\u201d, \u201cHigh\u201d and \u201cUnclear risk\u201d have been updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00415-025-13021-3","URL":"https:\/\/doi.org\/10.1007\/s00415-025-13021-3","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors did not receive support from any organisations for this submitted work. There are no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"124"}}